News | Cardiovascular Clinical Studies | September 12, 2017

Late-breaking Trial Presentations at ESC 2017

ESC Congress 2017 held Aug. 26-30 in Barcelona, Spain
 

ESC 2017 late breaking trial hot line study presentations.

September 12, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking Clinical Trial presentations highlighting the latest cardiovascular science. ESC 2017 includes 21 late-reaking clinical trials, presented and discussed in four Hot Line sessions, plus late breaking results from 12 registries and 12 clinical trial updates. Some of the key presentations with links to the article were:

• SPYRAL HTN-OFF MED Study: Results Show Efficacy, Safety of Renal Denervation

CASTLE-AF Study: Results Indicate Catheter Ablation of Atrial Fibrillation as First-Line Treatment for Heart Failure Patients

• CANTOS Trial: Designed to directly test the inflammatory hypothesis of atherothrombosis by randomly allocating post-myocardial infarction patients to one of three doses of canakinumab (a monoclonal antibody targeting interleukin 1-beta) or to placebo. 

• DETO2X-AMI: This registry-based randomized clinical trial done in 35 hospitals across Sweden examines if giving oxygen to patients with myocardial infarction is useful or if it actually does harm.

• COMPASS Trial: This study looks whether rivaroxaban, either alone or with aspirin, is superior to aspirin alone for the prevention of myocardial infarction, stroke and cardiovascular death in patients with stable coronary or peripheral artery disease.
 

EMANATE Trial: This study looks at apixaban versus conventional therapy in anticoagulation-naive patients with atrial fibrillation undergoing cardioversion.
 
LAACS Study: This randomized study examined whether surgical closure of the left atrial appendage (LAA) during open heart surgery protects the brain against thromboembolic damage.
 
VIVA Trial: Results of this study will reveal the mortality impact and cost-effectiveness of combined screening for abdominal aortic aneurysm (AAA), peripheral artery disease (PAD) and hypertension.
 
Phase II ORION 1 Trial: Looks at the impact of single or multiple injections of the first-in-class PCSK9 inhibitor inclirisan on low-density lipoprotein cholesterol . The study looked at establishing the dose and dosing frequency that will be required in phase III trials.
 
FOURIER Trial: This clinical trial update will show the efficacy and safety of evolocumab added to high-intensity or moderate-intensity statin therapy in patients with clinically evident atherosclerotic cardiovascular disease.

PURE Trial: Results will reveal the dose-response effect of fruit, vegetable and legume intake on cardiovascular disease  and mortality among 135,335 people aged 35 to 70 without prior cardiovascular disease from 18 countries on five continents.

CLARIFY Trial: Findings from the prospective international longitudinal registry of 32,703 outpatients with stable coronary artery disease will explain how low diastolic blood pressure and increased pulse pressure contribute to the J curve in hypertensive patients with coronary artery disease.

 

Other Key ESC 2017 Presentations

• MobiusHD Device Shows Promise in Treatment of Resistant Hypertension

• Biotronik's Orsiro Drug-Eluting Stent Outperforms Xience in BIOFLOW-V Trial

• Real-World Analysis Compares Safety, Effectiveness of Apixaban Versus Warfarin

• Titan Nitride Oxide Coated Stent is Noninferior to Synergy Stent

 

For more information: www.escardio.org

 

Late-breaking Trials From TCT, ACC, SCAI and HRS: 

SCAI 2017 Late-Breaking Clinical Trial Presentations

Heart Rhythm Society 2017 Late-Breaking Electrophysiology Trials

ACC 2017 Late-Breaking Trials

TCT 2016 Late-breaking Trials and First Reports

Related Content

Feature | ACC | By Melinda Taschetta-Millane

In April, the cardiology community converged face-to-face in Orlando for The American College of Cardiology’s (ACC22) ...

Home May 11, 2022
Home
News | ACC

April 12, 2022 – The American College of Cardiology (ACC) is establishing a new award in honor of Valentin Fuster, MD ...

Home April 12, 2022
Home
News | ACC
April 4, 2022 – Esperion presented two new analyses from its clinical development program of bempedoic acid (NEXLETOL) ...
Home April 04, 2022
Home
News | ACC

April 3, 2022 — egnite, Inc., an advanced technology digital health company focused on providing artificial intelligence ...

Home April 03, 2022
Home
News | ACC

April 3, 2022 — A new drug shows promise in providing relief to cardiomyopathy patients experiencing shortness of breath ...

Home April 03, 2022
Home
News | ACC

April 1, 2022 — Royal Philips, a global leader in health technology, announced new additions to its innovative ...

Home April 01, 2022
Home
News | ACC
March 31, 2022 – Healthcare AI solutions provider Aidoc will be delivering a live demonstration of its comprehensive AI ...
Home March 31, 2022
Home
News | ACC
March 31, 2022 – Experts from the Smidt Heart Institute at Cedars-Sinai, home to California’s top-ranked cardiology and ...
Home March 31, 2022
Home
News | ACC
March 31, 2022 – CathWorks has announced that the results of its most recent outcomes study on the CathWorks FFRangio ...
Home March 31, 2022
Home
News | ACC
February 15, 2022 — The American College of Cardiology’s Cardiovascular Summit Virtual (CV Summit) will feature three ...
Home February 15, 2022
Home
Subscribe Now